Drugs / SB012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02129439 | Apr 2014 → Jun 2017 | ulcerative colitis | Sterna Biologicals GmbH & Co. KG | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2018-06-05 | Sterna Biologicals GmbH & Co. KG | Results sterna biologicals presents detailed results from successful phase 2a study with GATA-3 specific DNAzyme formulation SB012 in patients with ulcerative colitis sterna-biologicals.com ↗
SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis |
| 2018-02-19 | Sterna Biologicals GmbH & Co. KG | Results sterna biologicals reports phase 2a study data demonstrating efficacy of its gata 3 specific dnazyme formulation sb012 in patients with ulcerative colitis sterna-biologicals.com ↗
SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis. |
| 2014-04-29 | Sterna Biologicals GmbH & Co. KG | Regulatory Introducing SB012 for the treatment of ulcerative colitis sterna-biologicals.com ↗
The SECURE trial (SB012 for the treatment of active ulcerative colitis) has been approved by regulatory agencies and will commence in May 2014. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-09-05 | Sterna Biologicals GmbH & Co. KG | sterna biologicals prepares for phase IIB clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis sterna-biologicals.com ↗ |
| 2018-06-05 | Sterna Biologicals GmbH & Co. KG | sterna biologicals presents detailed results from successful phase 2a study with GATA-3 specific DNAzyme formulation SB012 in patients with ulcerative colitis sterna-biologicals.com ↗ |
| 2018-05-29 | Sterna Biologicals GmbH & Co. KG | sterna biologicals announces data with gata-3 specific dnazyme SB012 to be presented at Digestive Disease Week® sterna-biologicals.com ↗ |
| 2018-02-19 | Sterna Biologicals GmbH & Co. KG | sterna biologicals reports phase 2a study data demonstrating efficacy of its gata 3 specific dnazyme formulation sb012 in patients with ulcerative colitis sterna-biologicals.com ↗ |
| 2014-04-29 | Sterna Biologicals GmbH & Co. KG | Introducing SB012 for the treatment of ulcerative colitis sterna-biologicals.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02129439 ↗ |
| Action | Inhibit | “By cleaving GATA-3 mRNA hgd40 reduces specific cytokine production” NCT02129439 ↗ |
| Modality | Oligonucleotide (other) | “The investigational product SB012 contains the DNAzyme hgd40” NCT02129439 ↗ |
| Route | Rectal | “The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route.” NCT02129439 ↗ |
| Target | GATA3 | “hgd40 that targets GATA-3” NCT02129439 ↗ |